To evaluate the response of ovarian cancers in different risk groups to immune checkpoint inhibitors (ICIs), we calculated the IPS score (including CTLA4 blocker and PD-1/PD-L1/PD-L2 blocker) was much significantly higher in the low-risk group patients (Figure 5C–5E). Here, CTLA4 is linked to ovarian carcinoma.